1, Hengrui Medical
Jiangsu hengrui Pharmaceutical Co., Ltd. is a medical and health enterprise engaged in medical innovation and R&D, producing and popularizing high-quality drugs. Founded in 1970, it was listed on the Shanghai Stock Exchange in 2000. By the end of 20 19, * * has more than 24,000 employees worldwide, and is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China.
It is also the lead unit of the National Anti-tumor Drug Technology Innovation Industry-University-Research Alliance, with the National Targeted Drug Engineering Technology Research Center and Postdoctoral Research Center.
2. Shi Yao Holding Group
National innovative enterprise, Shi Yao Holding Group Co., Ltd. is a national innovative enterprise integrating R&D, innovative drug production and sales. The whole group has 27,000 employees.
Listed companies in Hong Kong (0 1093. HK) are among the clubs with a market value of 100 billion. They are the constituent stocks of the Hang Seng Index and the first pharmaceutical stock in the 50 years since the index was compiled.
20 19 years, its subsidiary Sino-Norway (300765. SZ), successfully listed on the Growth Enterprise Market, Unacon realized a new era of "red chip +A" financing pattern.
3. China biopharmaceuticals
Sino Biopharmaceutical Limited is a comprehensive group pharmaceutical enterprise. The company mainly develops, produces and sells a variety of chemicals, biopharmaceuticals and modern preparations of traditional Chinese medicine, and applies advanced biotechnology and modern technology of traditional Chinese medicine to promote human health.
4. Mindray Medical
Mindray, headquartered in Shenzhen, provides medical device products to the global market.
Mindray has branches in more than 30 provinces, municipalities and autonomous regions in China, 39 overseas subsidiaries and 9 R&D centers around the world. There are more than 10000 employees in the world, of which R&D personnel account for nearly 26% and foreign employees account for more than 12%, coming from more than 30 countries and regions around the world, forming a huge global R&D, marketing and service network.
Mindray's main business covers life information and support, in vitro diagnosis and medical imaging. Through cutting-edge technological innovation, Mindray provides more perfect product solutions to help the world improve medical conditions and improve the efficiency of diagnosis and treatment.
5. Buchang Pharmaceutical
Shandong Buchang Pharmaceutical Co., Ltd. ("Buchang Pharmaceutical" for short) was established on 200 1 and completed the shareholding system reform on 20 12. 20 16 was approved by the IPO of the audit committee of China Securities Regulatory Commission in July, and successfully listed in 20118 10.
In the development of 19, Buchang Pharmaceutical has built a clear development strategy, focusing on serious diseases and cultivating large varieties. The company focuses on patented Chinese patent medicines and is committed to the modernization of Chinese medicine.
Give full play to the important role of traditional Chinese medicine in the field of cardiovascular and cerebrovascular diseases, and form a three-dimensional product pattern based on the cardiovascular and cerebrovascular market, covering the traditional advantages of Chinese patent medicines, focusing on serious diseases and cultivating large varieties.
6. Tasly Pharmaceutical Group Holding Company
Compound Danshen Dripping Pills is a landmark enterprise in the modernization of traditional Chinese medicine, which has been listed for many years and is recognized as a heavy variety in the market.
Significant progress has been made in the research and development of Shaoma Zhijing Granule, which has been approved by NMPA Drug Administration to treat Tourette's syndrome and chronic TIC disorder, and 43 drugs (including generic drugs, 9 of them) have entered the clinical stage.
Among them, the layout of modern Chinese medicine, the research and development projects of new drugs of FDA and Compound Danshen Dripping Pills (T89) are progressing smoothly. Two modern Chinese medicine products, Zhuo Zhi Granule and Compound Danshen Dripping Pill, have been applied for production, and the application materials for indications of Compound Danshen Dripping Pill and Sugar Net have been submitted to CDE.
7. Shanghai Fosun Pharma
We have established high-efficiency chemical innovation drug platform, biomedical platform, high-value generic drug platform and cellular immunity platform. As of 20 18, the company has nearly 2000 R&D employees.
Up to the interim report of 20 19, the company has completed generic drugs, innovative drugs, bio-similar drugs and generic drugs, including: 2 innovative drugs 12, 233 innovative drugs with small molecule consistency evaluation, 20 bio-similar drugs, 29 international standard generic drugs 129, 2 traditional Chinese medicines and 54 consistency evaluations. In addition, 23 projects have been introduced.
8. Zheng Da Tianqing Pharmaceutical Company
Zheng Da Tianqing Pharmaceutical Co., Ltd. is an innovative pharmaceutical group enterprise integrating scientific research, production and sales. It is a famous R&D and production base for liver diseases and anti-tumor drugs. 20 19 certified varieties 14, ranking first in the industry.
Promote the transformation of enterprises from "one liver alone" to "two cores and many strengths" and continue to strengthen the construction of core competitiveness; As the leading comprehensive empowerment platform in the world and China, it has continuously improved its position in the global market and has the full layout of CROCMO/CDMO industry.
The preclinical CRO and small molecule CDMO of traditional business grew steadily, while the clinical CRO and cell/gene therapy CDMO of new business grew rapidly.
9. Wuxi pharmatech
CDMO/CMO small molecule drug service involves more than 800 new drug molecules, including 40 phase III clinical trials and 65,438+06 projects listed in batches. In the first half of 2065,438+09, Wuxi PharmaTech also helped domestic customers complete 65,438+00 clinical trials of new research drugs, and obtained 65,438+065,438+0 clinical trials.
By June 30th, the company had obtained clinical trial licenses for 45 projects, and completed clinical trial applications for 65 new research drugs for domestic customers on June 30th.
10, Huahai Pharmaceutical
Huahai Pharmaceutical Co., Ltd. is the first pharmaceutical company in the United States to obtain FDA certification, and the first company in the United States to realize large-scale preparation sales in China, occupying a place in the world's high-end pharmaceutical market.